Pharma major Lupin has received tentative approval for its Fosaprepitant for Injection, 150-mg Single-Dose Vial, from the United States Food and Drug Administration.
Lupin's Fosaprepitant for Injection, a generic version of Merck's Emend for Injection, is indicated for adults in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly/ moderately emetogenic cancer chemotherapy, including high-dose cisplatin. Shares of Lupin edged down 1.33 per cent at ₹855.95 on the BSE.